Drug Combo May Obviate Chemotherapy in ALL
- PMID: 33168588
- DOI: 10.1158/2159-8290.CD-NB2020-99
Drug Combo May Obviate Chemotherapy in ALL
Abstract
A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The study found that 60% of patients had molecular responses after two cycles of blinatumomab and 71% had molecular responses after five cycles.
©2020 American Association for Cancer Research.
Comment on
-
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical